Current concepts in SARS treatment.
Current concepts in SARS treatment.
复制标题
DOI：
10.1007/s10156-003-0296-9
复制
发表时间：
2004-02
期刊：
影响因子：
--
通讯作者：
Iwamoto A
中科院分区：
文献类型：
--
作者：
Fujii T;Nakamura T;Iwamoto A
自2003年初以来，严重急性呼吸系统综合症（SARS）的爆发引起了全世界的极大关注和恐惧。这种疾病现在似乎得到了控制；但是，必须强调SARS可能卷土重来的可能性。虽然有许多临床实验的报道，但对SARS的治疗基本上是道听途说，到目前为止还没有达成治疗共识。我们总结了14份临床报告，并试图评估各种治疗方案的有效性。从流行病开始，类固醇和利巴韦林的联合治疗被广泛使用。总的来说，使用类固醇治疗SARS似乎是有益的，但最佳的治疗时间、剂量和持续时间尚未确定。另一方面，给予利巴韦林既没有明显降低气管插管率，也没有明显降低死亡率。此外，利巴韦林还具有明显的毒性，如溶血性贫血。一些初步试验和体外数据表明，用干扰素治疗SARS是可能的。其他药物，包括HIV蛋白酶抑制剂甘草酸和恢复期血浆，仍有待评估。
The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated.